Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics company information, Employees & Contact Information

BrainStorm Cell Therapeutics Inc. (NASDAQ) develops autologous stem cell therapies for neurodegenerative disorders such as ALS, MS, and Parkinson’s disease. These diseases have limited treatment options and represent unmet medical needs. NurOwn® is BrainStorm’s proprietary process for differentiating autologous mesenchymal stem cells (MSC) into neurotrophic factor (NTF)-secreting cells, transplanted at or near the affected tissue site. Our technology converts MSCs into a living drug delivery system for NTFs. We have proof-of-concept in various animal models of neurodegenerative diseases, including Parkinson's, Huntington's, ALS, MS, and peripheral nerve injury. We have completed two single-arm clinical trials in ALS patients in Israel, demonstrating good safety and tolerability profiles and strong efficacy signals. We also finalized a Phase 3 randomized, double-blind, placebo-controlled clinical trial at multiple US sites, supported by a $16 million USD grant from the California Institute for Regenerative Medicine (CIRM) and another grant from the ALS Association. Currently, we are planning a Phase 3b clinical trial of NurOwn® in ALS under a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA). For more information, visit www.brainstorm-cell.com

Company Details

Employees
32
Founded
-
Address
12 Bazel Street,
Phone
646-666-3188
Email
in****@****ell.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Kiryat Aryeh, Petach Tikva
Looking for a particular Brainstorm Cell Therapeutics employee's phone or email?

Brainstorm Cell Therapeutics Questions

News

BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS - PR Newswire

BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS PR Newswire

BrainStorm Cell Therapeutics Sets Key Q2 Earnings Call: Stem Cell Pipeline and Financial Updates Coming - Stock Titan

BrainStorm Cell Therapeutics Sets Key Q2 Earnings Call: Stem Cell Pipeline and Financial Updates Coming Stock Titan

BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire

BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update PR Newswire

BrainStorm Cell Faces Nasdaq Exit: What the OTCQB Switch Means for Investors and NurOwn Program - Stock Titan

BrainStorm Cell Faces Nasdaq Exit: What the OTCQB Switch Means for Investors and NurOwn Program Stock Titan

BrainStorm to Present Biomarker Insights Supporting NurOwn's Mechanism of Action and Clinical Impact at the 2025 ALS Drug Development Summit - PR Newswire

BrainStorm to Present Biomarker Insights Supporting NurOwn's Mechanism of Action and Clinical Impact at the 2025 ALS Drug Development Summit PR Newswire

Breaking ALS Treatment News: FDA Gives Green Light to BrainStorm's Crucial Phase 3b NurOwn Trial - Stock Titan

Breaking ALS Treatment News: FDA Gives Green Light to BrainStorm's Crucial Phase 3b NurOwn Trial Stock Titan

FDA staff reviewers raise concerns over BrainStorm Cell's ALS therapy - Reuters

FDA staff reviewers raise concerns over BrainStorm Cell's ALS therapy Reuters

FDA AdComm Votes Down BrainStorm Cell Therapeutics’ ALS Cell Therapy NurOwn - CGTLive®

FDA AdComm Votes Down BrainStorm Cell Therapeutics’ ALS Cell Therapy NurOwn CGTLive®

BrainStorm Cell Therapeutics and Minaris partner on manufacturing NurOwn for trial - Clinical Trials Arena

BrainStorm Cell Therapeutics and Minaris partner on manufacturing NurOwn for trial Clinical Trials Arena

BrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQB - PR Newswire

BrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQB PR Newswire

BrainStorm Cell Therapeutics Investors Advance FDA Feedback Suit - Bloomberg Law News

BrainStorm Cell Therapeutics Investors Advance FDA Feedback Suit Bloomberg Law News

BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire

BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update PR Newswire

BrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn® - PR Newswire

BrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn® PR Newswire

BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials - PR Newswire

BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials PR Newswire

FDA Review of Citizen Petition Offers a Fresh Look at NurOwn®'s Evidence of Treatment Effectiveness - PR Newswire

FDA Review of Citizen Petition Offers a Fresh Look at NurOwn®'s Evidence of Treatment Effectiveness PR Newswire

BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn® in ALS - PR Newswire

BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn® in ALS PR Newswire

BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq - PR Newswire

BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq PR Newswire

BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing - PR Newswire

BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing PR Newswire

BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update - PR Newswire

BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update PR Newswire

BrainStorm Cell Therapeutics to Announce Third Quarter Results and Provide a Corporate Update - PR Newswire

BrainStorm Cell Therapeutics to Announce Third Quarter Results and Provide a Corporate Update PR Newswire

Cell therapy weekly: Phase III results for BrainStorm Cell Therapeutics’ ALS therapy lead to rejection by FDA committee - RegMedNet

Cell therapy weekly: Phase III results for BrainStorm Cell Therapeutics’ ALS therapy lead to rejection by FDA committee RegMedNet

Important Notice to Long-Term Shareholders of Alto Neuroscience, Inc. (NYSE: ANRO); Brainstorm Cell Therapeutics Inc. (OTC: BCLI); Flywire Corporation (NASDAQ: FLYW); and Ibotta, Inc. (NYSE: IBTA): Grabar Law Office is Investigating Claims on Your Beh - GlobeNewswire

Important Notice to Long-Term Shareholders of Alto Neuroscience, Inc. (NYSE: ANRO); Brainstorm Cell Therapeutics Inc. (OTC: BCLI); Flywire Corporation (NASDAQ: FLYW); and Ibotta, Inc. (NYSE: IBTA): Grabar Law Office is Investigating Claims on Your Beh GlobeNewswire

Brainstorm Cell Therapeutics Appeals Nasdaq Delisting - Investing.com

Brainstorm Cell Therapeutics Appeals Nasdaq Delisting Investing.com

Brainstorm Cell Therapeutics Crashes 42% After Voluntary Nasdaq Delisting Announcement - Sahm

Brainstorm Cell Therapeutics Crashes 42% After Voluntary Nasdaq Delisting Announcement Sahm

ALS Community Petitions FDA To Reconsider BrainStorm’s NurOwn, Pointing to Recent Survival Data - BioSpace

ALS Community Petitions FDA To Reconsider BrainStorm’s NurOwn, Pointing to Recent Survival Data BioSpace

Brainstorm Cell Therapeutics: Balancing Hope and Financial Hurdles - TipRanks

Brainstorm Cell Therapeutics: Balancing Hope and Financial Hurdles TipRanks

BrainStorm's ALS cell therapy resoundingly rejected by FDA advisers - Fierce Biotech

BrainStorm's ALS cell therapy resoundingly rejected by FDA advisers Fierce Biotech

BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer - PR Newswire

BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer PR Newswire

Brainstorm Cell Therapeutics Faces Nasdaq Delisting Notice - TipRanks

Brainstorm Cell Therapeutics Faces Nasdaq Delisting Notice TipRanks

BCLI - Brainstorm Cell Therapeutics I Latest Stock News & Market Updates - Stock Titan

BCLI - Brainstorm Cell Therapeutics I Latest Stock News & Market Updates Stock Titan

Brainstorm's cell therapy for ALS lacks convincing clinical data for FDA submission, agency concludes - statnews.com

Brainstorm's cell therapy for ALS lacks convincing clinical data for FDA submission, agency concludes statnews.com

NurOwn, phase 2, randomized, clinical trial in patients with ALS - Neurology® Journals

NurOwn, phase 2, randomized, clinical trial in patients with ALS Neurology® Journals

Stem cell therapy for ALS fails a large clinical trial - BioPharma Dive

Stem cell therapy for ALS fails a large clinical trial BioPharma Dive

BrainStorm climbs on stem cell data from small multiple sclerosis trial - Fierce Biotech

BrainStorm climbs on stem cell data from small multiple sclerosis trial Fierce Biotech

BrainStorm Cell Therapeutics Promotes Dr. Stacy Lindborg to Co-Chief Executive Officer - citybiz

BrainStorm Cell Therapeutics Promotes Dr. Stacy Lindborg to Co-Chief Executive Officer citybiz

Treating neurodegenerative diseases with stem cell therapy - Nature

Treating neurodegenerative diseases with stem cell therapy Nature

BrainStorm Cell Therapeutics Crashes After Hours On Nasdaq Delisting Notice; Retail Sees 'Buy Time' - Stocktwits

BrainStorm Cell Therapeutics Crashes After Hours On Nasdaq Delisting Notice; Retail Sees 'Buy Time' Stocktwits

Brainstorm Announces Positive Results for NurOwn Phase II U.S. Clinical Trial - The ALS Association

Brainstorm Announces Positive Results for NurOwn Phase II U.S. Clinical Trial The ALS Association

BrainStorm Announces Positive Top Line Results from the U.S. Phase 2 Study of NurOwn® in Patients with Amyotrophic Lateral Sclerosis (ALS) - PR Newswire

BrainStorm Announces Positive Top Line Results from the U.S. Phase 2 Study of NurOwn® in Patients with Amyotrophic Lateral Sclerosis (ALS) PR Newswire

BrainStorm Cell Therapeutics Announces Positive Interim Safety Analysis - Investing News Network

BrainStorm Cell Therapeutics Announces Positive Interim Safety Analysis Investing News Network

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q4 2022 Earnings Call Transcript - Insider Monkey

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q4 2022 Earnings Call Transcript Insider Monkey

BrainStorm Cell Therapeutics to move from Nasdaq to OTCQB after delisting; shares down - MSN

BrainStorm Cell Therapeutics to move from Nasdaq to OTCQB after delisting; shares down MSN

BrainStorm to Present Phase 2 Progressive MS Study Results in Oral Presentation at 37th Congress of ECTRIMS - MarketScreener

BrainStorm to Present Phase 2 Progressive MS Study Results in Oral Presentation at 37th Congress of ECTRIMS MarketScreener

Brainstorm Cell Therapeutics (BCLI) Stock Price, News & Analysis - MarketBeat

Brainstorm Cell Therapeutics (BCLI) Stock Price, News & Analysis MarketBeat

Brainstorm Cell Therapeutics (BCLI) - Zacks Investment Research

Brainstorm Cell Therapeutics (BCLI) Zacks Investment Research

Lisa Wittenberg, face of UCI’s groundbreaking ALS clinical trial, dies at age 46 - Orange County Register

Lisa Wittenberg, face of UCI’s groundbreaking ALS clinical trial, dies at age 46 Orange County Register

Top Brainstorm Cell Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant